Marcella Reale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4389889/publications.pdf

Version: 2024-02-01

140	4,958	100601	124990
papers	citations	38 h-index	64 g-index

144	144	144	7977
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Muscarinic Receptors Expression in the Peripheral Blood Cells Differentiate Dementia with Lewy Bodies from Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 323-330.	1.2	4
2	Neuroprotective Potential of Bacopa monnieri: Modulation of Inflammatory Signals. CNS and Neurological Disorders - Drug Targets, 2022, 21, .	0.8	3
3	Evaluation of Cell Migration and Cytokines Expression Changes under the Radiofrequency Electromagnetic Field on Wound Healing In Vitro Model. International Journal of Molecular Sciences, 2022, 23, 2205.	1.8	11
4	Wound-Healing Promotion and Anti-Inflammatory Properties of Carvacrol Prodrugs/Hyaluronic Acid Formulations. Pharmaceutics, 2022, 14, 1468.	2.0	3
5	Serum microRNA Levels in Diabetes Mellitus. Diagnostics, 2021, 11, 284.	1.3	9
6	Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment. Frontiers in Psychiatry, 2021, 12, 536257.	1.3	53
7	Cholinergic Modulation of the Immune System in Neuroinflammatory Diseases. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.0	24
8	nAChRs gene expression and neuroinflammation in APPswe/PS1dE9 transgenic mouse. Scientific Reports, 2021, 11, 9711.	1.6	8
9	Wound Repair and Extremely Low Frequency-Electromagnetic Field: Insight from In Vitro Study and Potential Clinical Application. International Journal of Molecular Sciences, 2021, 22, 5037.	1.8	24
10	Assessment of the Vanillin Anti-Inflammatory and Regenerative Potentials in Inflamed Primary Human Gingival Fibroblast. Mediators of Inflammation, 2021, 2021, 1-9.	1.4	10
11	Pidotimod and Immunological Activation in Individuals Infected with HIV. Current HIV Research, 2021, 19, 260-268.	0.2	5
12	In Vitro Wound-Healing Properties of Water-Soluble Terpenoids Loaded on Halloysite Clay. Pharmaceutics, 2021, 13, 1117.	2.0	9
13	Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV. Nutrients, 2021, 13, 4412.	1.7	0
14	Anti-cancer effects of polyphenols via targeting p53 signaling pathway: updates and future directions. Biotechnology Advances, 2020, 38, 107385.	6.0	96
15	Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimerâ€™s Disease: Present and future applications. Brain Research, 2020, 1727, 146535.	1.1	21
16	Short ELF-EMF Exposure Targets SIRT1/Nrf2/HO-1 Signaling in THP-1 Cells. International Journal of Molecular Sciences, 2020, 21, 7284.	1.8	25
17	Critical Review on the Presence of Phthalates in Food and Evidence of Their Biological Impact. International Journal of Environmental Research and Public Health, 2020, 17, 5655.	1.2	177
18	Cholinergic Markers and Cytokines in OSA Patients. International Journal of Molecular Sciences, 2020, 21, 3264.	1.8	9

#	Article	IF	Citations
19	Possible Correlation between Cholinergic System Alterations and Neuro/Inflammation in Multiple Sclerosis. Biomedicines, 2020, 8, 153.	1.4	29
20	Relationship of Wine Consumption with Alzheimerâ€™s Disease. Nutrients, 2020, 12, 206.	1.7	26
21	Evaluation of Salivary Cytokines and Vitamin D Levels in Periodontopathic Patients. International Journal of Molecular Sciences, 2020, 21, 2669.	1.8	44
22	Circulating levels of Apelin-36 in patients with mild to moderate psoriasis. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 646-651.	0.8	3
23	Network between Cytokines, Cortisol and Occupational Stress in Gas and Oilfield Workers. International Journal of Molecular Sciences, 2020, 21, 1118.	1.8	4
24	Human Gingival Fibroblasts Exposed to Extremely Low-Frequency Electromagnetic Fields: In Vitro Model of Wound-Healing Improvement. International Journal of Molecular Sciences, 2019, 20, 2108.	1.8	23
25	Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges. Frontiers in Cellular Neuroscience, 2019, 13, 107.	1.8	18
26	Synthesis and biological evaluation of novel analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 194-198.	1.0	10
27	Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation. Scientific Reports, 2018, 8, 1319.	1.6	41
28	Probiotics and Anti-inflammatory Processes in HIV Infection. , 2018, , 295-307.		0
29	Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-Î² Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2018, 62, 467-476.	1.2	18
30	Immune and Inflammatory-Mediated Disorders: From Bench to Bedside. Journal of Immunology Research, 2018, 2018, 1-3.	0.9	5
31	The Role of Immunosenescence in Neurodegenerative Diseases. Mediators of Inflammation, 2018, 2018, 1-12.	1.4	91
32	Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-Î²-Treated Relapsingâ€“Remitting-Multiple Sclerosis Patients. Frontiers in Immunology, 2018, 9, 1240.	2.2	17
33	MicroRNA in SjÃ¶grenâ€™s Syndrome: Their Potential Roles in Pathogenesis and Diagnosis. Journal of Immunology Research, 2018, 2018, 1-8.	0.9	37
34	Cytokines, Hepatic Fibrosis, and Antiretroviral Therapy Role in Neurocognitive Disorders HIV Related. AIDS Research and Human Retroviruses, 2017, 33, 246-253.	0.5	21
35	Targeting Arachidonic Acid Pathway-Associated NF-ÎºB in Pancreatic Cancer. , 2017, , 403-411.		1
36	Microbiota and Probiotics in Health and HIV Infection. Nutrients, 2017, 9, 615.	1.7	53

#	Article	IF	Citations
37	Editorial: Neurodegenerative Disorders: Synthesis, Drug Delivery Strategies and Biological Evaluation of New Therapeutic Agents. Central Nervous System Agents in Medicinal Chemistry, 2017, 17, 89.	0.5	1
38	Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis. Current Medicinal Chemistry, 2017, 24, 176-192.	1.2	18
39	Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications. Current Pharmaceutical Design, 2017, 23, 4475-4483.	0.9	15
40	Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation. Current Alzheimer Research, 2017, 14, 1140-1148.	0.7	161
41	Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis. Central Nervous System Agents in Medicinal Chemistry, 2017, 17, 109-115.	0.5	25
42	Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2016, 17, 1035.	1.8	26
43	Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients. International Journal of Molecular Sciences, 2016, 17, 2009.	1.8	25
44	Development of glycine-Î±-methyl-proline-containing tripeptides with neuroprotective properties. European Journal of Medicinal Chemistry, 2016, 108, 553-563.	2.6	13
45	Effect of Environmental Extremely Low-Frequency Electromagnetic Fields Exposure on Inflammatory Mediators and Serotonin Metabolism in a Human Neuroblastoma Cell Line. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1203-1215.	0.8	10
46	Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study. Nutrients, 2015, 7, 8335-8347.	1.7	47
47	mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes. PLoS ONE, 2015, 10, e0139644.	1.1	28
48	Effects of extremely low frequency electromagnetic field (ELF-EMF) on catalase, cytochrome P450 and nitric oxide synthase in erythro-leukemic cells. Life Sciences, 2015, 121, 117-123.	2.0	44
49	Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients. International Immunopharmacology, 2015, 29, 152-157.	1.7	28
50	Experimental model for ELF-EMF exposure: Concern for human health. Saudi Journal of Biological Sciences, 2015, 22, 75-84.	1.8	68
51	Neuronal Cellular Responses to Extremely Low Frequency Electromagnetic Field Exposure: Implications Regarding Oxidative Stress and Neurodegeneration. PLoS ONE, 2014, 9, e104973.	1.1	58
52	P1-090: AGE- AND BRAIN AREAS-RELATED EXPRESSION OF CYTOKINES, CHOLINESTERASES, AND NICOTINIC ACETYLCHILINE RECEPTORS. , 2014, 10, P335-P335.		0
53	Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimerâ€™s Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway. Current Alzheimer Research, 2014, 11, 608-622.	0.7	45
54	Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies. CNS and Neurological Disorders - Drug Targets, 2014, 13, 467-477.	0.8	14

#	Article	IF	Citations
55	Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1294-1303.	0.8	93
56	Extremely low frequency electromagnetic field and wound healing: implication of cytokines as biological mediators. European Cytokine Network, 2013, 24, 1-10.	1.1	86
57	Cytokines and T cells in atopic dermatitis. European Cytokine Network, 2013, 24, 37-44.	1.1	72
58	Editorial (Hot Topic:Modulation of Cholinergic System Activity in Neuronal and Non-Neuronal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 2013, 12, 107-108.	1.1	1
59	New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors. Recent Patents on CNS Drug Discovery, 2013, 8, 123-141.	0.9	32
60	Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2013, 12, 117-128.	1.1	23
61	Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients. International Journal of Molecular Sciences, 2012, 13, 12656-12664.	1.8	50
62	Daily intake ofLactobacillus caseiShirota increases natural killer cell activity in smokers. British Journal of Nutrition, 2012, 108, 308-314.	1.2	60
63	Relationship between Inflammatory Mediators, A? Levels and ApoE Genotype in Alzheimer Disease. Current Alzheimer Research, 2012, 9, 447-457.	0.7	50
64	Well-Being at Work and Immune Response. Advances in Neuroimmune Biology, 2012, 3, 297-300.	0.7	0
65	Job strain in different types of employment affects the immune response. Work, 2012, 41, 2950-2954.	0.6	9
66	Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)â€1 in electromagnetic fieldâ€exposed THPâ€1 cells. Journal of Cellular Physiology, 2012, 227, 2767-2774.	2.0	37
67	Mitochondria as an Easy Target to Oxidative Stress Events in Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2012, 11, 430-438.	0.8	38
68	Effects of Palladium Nanoparticles on the Cytokine Release from Peripheral Blood Mononuclear Cells of Palladium-Sensitized Women. Journal of Occupational and Environmental Medicine, 2011, 53, 1054-1060.	0.9	36
69	Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neuroscience, 2011, 12, 13.	0.8	97
70	Parkinsonâ€™s Disease and Cytokines. , 2011, , 343-355.		1
71	Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach. CNS and Neurological Disorders - Drug Targets, 2011, 10, 928-935.	0.8	4
72	Cytokines and Alzheimerâ€™s Disease. , 2011, , 329-342.		0

#	Article	IF	Citations
73	Multiple Approaches to Analyse the Data for Rat Brain Acetylcholinesterase Inhibition by Cyclophosphamide. Neurochemical Research, 2010, 35, 1501-1509.	1.6	8
74	Antiinflammatory effects in THPâ€1 cells treated with verbascoside. Phytotherapy Research, 2010, 24, 1398-1404.	2.8	107
75	The effect of deproteinized bovine bone on osteoblast growth factors and proinflammatory cytokine production. Clinical Oral Implants Research, 2010, 21, 650-655.	1.9	27
76	Extremely low frequency electromagnetic fields modulate expression of inducible nitric oxide synthase, endothelial nitric oxide synthase and cyclooxygenase-2 in the human keratinocyte cell line HaCat: potential therapeutic effects in wound healing. British Journal of Dermatology, 2010, 162, 258-266.	1.4	89
77	Neuroinflammation, AD, and Dementia. International Journal of Alzheimer's Disease, 2010, 2010, 1-2.	1.1	12
78	Anti-Inflammatory Properties of Acetylcholinesterase Inhibitors Administred in Alzheimers Disease. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2009, 8, 85-100.	1.1	10
79	Blood natural killer activity is reduced in men with occupational stress and job insecurity working in a university. International Archives of Occupational and Environmental Health, 2009, 82, 787-794.	1.1	29
80	Synthesis, Biological Evaluation, and Docking Studies of N-Substituted Acetamidines as Selective Inhibitors of Inducible Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2009, 52, 1481-1485.	2.9	31
81	Peripheral cytokines profile in Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2009, 23, 55-63.	2.0	452
82	Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1229-1241.	1.1	76
83	Editorial [Hot Topic:Anti-Inflammatory Strategy: Old Ally or New Promise in Therapy (Guest Editor:) Tj ETQq1 1 0.784314 rgBT /Overlo	1.1	0
84	Peripheral Chemokine Receptors, Their Ligands, Cytokines and Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 147-159.	1.2	99
85	The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacology, 2006, 50, 606-613.	2.0	51
86	Modulation of MCP-1 and iNOS by 50-Hz sinusoidal electromagnetic field. Nitric Oxide - Biology and Chemistry, 2006, 15, 50-57.	1.2	50
87	Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1? and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Experimental Gerontology, 2005, 40, 165-171.	1.2	87
88	Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. Experimental Gerontology, 2005, 40, 605-611.	1.2	45
89	MCP-1 and MIP-2 expression and production in BB diabetic rat: Effect of chronic hypoxia. Molecular and Cellular Biochemistry, 2005, 276, 105-111.	1.4	13
90	Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. Journal of Neuroimmunology, 2004, 148, 162-171.	1.1	112

#	Article	IF	Citations
91	IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. Experimental Gerontology, 2004, 39, 653-657.	1.2	29
92	Alzheimer Patients Treated With an AchE Inhibitor Show Higher IL-4 and Lower IL-1Î² Levels and Expression in Peripheral Blood Mononuclear Cells. Journal of Clinical Psychopharmacology, 2004, 24, 314-321.	0.7	51
93	In vitro effects of platinum compounds on lymphocyte proliferation and cytokine release. Annals of Clinical and Laboratory Science, 2004, 34, 195-202.	0.2	12
94	Different effects of platinum, palladium, and rhodium salts on lymphocyte proliferation and cytokine release. Annals of Clinical and Laboratory Science, 2004, 34, 299-306.	0.2	22
95	Interferon Î²-1b modulates MCP-1 expression and production in relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2002, 123, 170-179.	1.1	25
96	Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunology, Immunotherapy, 2002, 51, 91-98.	2.0	28
97	MCP-1 and MIP-2 response in Trichinella spiralis infected mice treated with 4-deoxypyridoxine (4-DPD). Immunology Letters, 2002, 83, 31-37.	1.1	7
98	Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee. Immunology Letters, 2002, 80, 105-111.	1.1	38
99	Inhibition of MCP-1 and MIP-2 transcription and translation by mimosine in muscle tissue infected with the parasite Trichinella spiralis. Molecular and Cellular Biochemistry, 2002, 229, 129-137.	1.4	15
100	Effects of low frequency electromagnetic fields on expression of lymphocyte subsets and production of cytokines of men and women employed in a museum. Science of the Total Environment, 2001, 270, 13-20.	3.9	27
101	Differential expression and secretion of RANTES and MCP-1 in activated peripheral blood mononuclear cell cultures of atopic subjects. Immunology Letters, 2001, 76, 7-14.	1.1	9
102	Elevated Circulating Levels of Monocyte Chemoattractant Protein-1 in Patients With Restenosis After Coronary Angioplasty. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 327-334.	1.1	208
103	RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-Î²-1b. Journal of Neuroimmunology, 2000, 107, 100-107.	1.1	60
104	Impact of extremely low frequency electromagnetic fields on CD4 expression in peripheral blood mononuclear cells. Molecular and Cellular Biochemistry, 1999, 201, 49-55.	1.4	14
105	Effect of Electromagnetic Fields on Several CD Markers and Transcription and Expression of CD4. Immunobiology, 1999, 201, 36-48.	0.8	7
106	Peripheral blood mononuclear cell production of interleukin-8 and IL-8-dependent neutrophil function in hypercholesterolemic patients. Atherosclerosis, 1999, 146, 345-350.	0.4	31
107	Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw. British Journal of Haematology, 1998, 103, 798-803.	1.2	28
108	Transforming growth factor Î²1 induces IL-1 receptor antagonist production and gene expression in rat vascular smooth muscle cells. Atherosclerosis, 1998, 136, 377-382.	0.4	17

#	Article	IF	Citations
109	Serum Levels of Soluble Adhesion Molecules in Chronic Renal Failure and Dialysis Patients. Nephron, 1998, 79, 399-407.	0.9	107
110	Will MCP-1 and RANTES Take Center Stage in Inflammatory Diseases Including Asthma?. Allergy and Asthma Proceedings, 1998, 19, 121-123.	1.0	9
111	Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cellâ€deficient W/W V mice. FASEB Journal, 1998, 12, 1693-1700.	0.2	78
112	Impact of Rantes and MCP-1 Chemokines on In Vivo Basophilic Cell Recruitment in Rat Skin Injection Model and Their Role in Modifying the Protein and mRNA Levels for Histidine Decarboxylase. Blood, 1997, 89, 4120-4127.	0.6	136
113	Influence of Interleukin-1 Receptor Antagonist on [3H] Serotonin and Histamine Release by Rat Basophilic Leukemia-2H3 Cells. Annals of the New York Academy of Sciences, 1997, 832, 223-232.	1.8	3
114	Infra-red laser irradiation enhances interleukin-1 receptor antagonist, increases 3H-thymidine incorporation and the release of [3H]arachidonic acid in human monocytes. Molecular and Cellular Biochemistry, 1997, 169, 51-59.	1.4	3
115	RANTES is a pro-inflammatory chemokine and chemoattracts basophil cells to extravascular sites. , 1997, 183, 352-358.		22
116	Increased Transforming Growth Factor-Î² Production and Gene Expression by Peripheral Blood Monocytes of Hypertensive Patients. Hypertension, 1997, 30, 134-139.	1.3	43
117	Generation of TNFÎ±, IFNÎ³, IL-6, IL-4 and IL-10 in mouse serum from trichinellosis: effect of the anti-inflammatory compound 4-deoxypyridoxine (4-DPD). Immunology Letters, 1996, 49, 179-184.	1.1	34
118	Effect of interleukin-1 receptor antagonist (IL-1RA) on histamine and serotonin release by rat basophilic leukemia cells (RBL-2H3) and peritoneal mast cells. Molecular and Cellular Biochemistry, 1996, 155, 61-68.	1.4	7
119	The down-regulation of IL-6-stimulated fibrinogen steady state mRNA and protein levels by human recombinant IL-1 is not PGE2-dependent: Effects of IL-1 receptor antagonist (IL-1RA). Molecular and Cellular Biochemistry, 1995, 142, 171-178.	1.4	17
120	Synergistic Activation of Serum Amyloid a (SAA) by IL-6 and IL-1 in Combination on Human Hep 3B Hepatoma Cell Line. Role of PGE2 and IL-1 Receptor Antagonist. Immunological Investigations, 1995, 24, 523-535.	1.0	28
121	Modulation of rat vascular smooth muscle cell (VSMC) proliferation by cysteinyl leukotriene D4: a role for mediation of interleukin 1. Atherosclerosis, 1995, 113, 11-18.	0.4	19
122	Cysteinyl-leukotriene D4 induced IL-1Î² expression and release in rat vascular smooth muscle cells. Atherosclerosis, 1995, 115, 181-189.	0.4	10
123	Effect of the antirheumatic agent Tenidap on CD3, CD4, and CD8 expression and interleukin-1 and leukotriene B₄ secretion in human peripheral blood mononuclear cells. Biochemistry and Cell Biology, 1994, 72, 397-402.	0.9	4
124	Bacillus Calmette-Guï¿½rin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients. Cancer Immunology, Immunotherapy, 1994, 38, 365-371.	2.0	30
125	Human recombinant interleukin-1 receptor antagonist (hrIL-1RA) inhibits prostaglandin E2 (PGE2) generation but not alkaline phosphatase activity in in vivo chronic granulomatous tissue induced by KMnO4. Immunology Letters, 1993, 37, 1-6.	1.1	5
126	Inhibition of Granuloma Formation Induced by Potassium Permanganate in the Mouse by a Specific Human Recombinant Receptor Antagonist for Interleukin-1 (hrIL-1ra). Cellular Immunology, 1993, 147, 446-457.	1.4	12

#	Article	IF	Citations
127	Granulocyte-macrophage colony stimulating factor potentiates human polymorphonuclear leukocyte aggregation responses to formyl-methionyl-leucyl-phenylalanine. Immunology Letters, 1992, 32, 71-79.	1.1	7
128	Human recombinant interleukin-1 receptor antagonist (hrIL-1ra) enhances the stimulatory effect of interleukin-2 on natural killer cell activity against molt-4 target cells. International Journal of Immunopharmacology, 1992, 14, 987-993.	1.1	0
129	Blocking the interleukin-1 receptor inhibits leukotriene B4 and prostaglandin E2 generation in human monocyte cultures. Cellular Immunology, 1992, 145, 199-209.	1.4	26
130	Inhibition of leukotriene B4(LTB4) by recombinant interleukin-1 receptor antagonist (IL-1RA) on human monocytes. Agents and Actions, 1992, 36, C93-C95.	0.7	1
131	Inhibition of leukotriene B4(LTB4) by recombinant interleukin-1 receptor antagonist (IL-1RA) on human monocytes. Agents and Actions, 1992, 36, C93-C95.	0.7	0
132	Human recombinant interleukin-1 receptor antagonist inhibits lymphocyte blastogenesis induced by concanavalin A Restorative effect of hrIL-1. FEBS Letters, 1991, 286, 137-141.	1.3	14
133	Enhancing Effect of Electromagnetic Exposure on Calciumionophore (A23187), but Not IL-1, Induced Txa2 Release by Human Neutrophils. International Journal of Immunopathology and Pharmacology, 1991, 4, 55-60.	1.0	6
134	Reduced mitogen stimulation of DNA synthesis in human lymphocytes by a human recombinant interleukin-1 receptor antagonist. Immunology Letters, 1991, 28, 19-25.	1.1	14
135	Lipoxins A4 and B4 inhibit leukotriene B4 generation from human neutrophil leukocyte suspensions. Immunology Letters, 1990, 24, 237-242.	1.1	8
136	Leukocyte inhibitory factor activates human neutrophils and macrophages to release leukotriene B4 and thromboxanes. Cytokine, 1990, 2, 142-148.	1.4	12
137	Restoration of anti-interleukin-1 depressed natural killer activity by human recombinant interferon Î± or Î³, human recombinant interleukin-2 and indomethacin. International Journal of Immunopharmacology, 1988, 10, 907-911.	1.1	12
138	Lipoxin A augments release of thromboxane from human polymorphonuclear leukocyte suspensions. FEBS Letters, 1987, 225, 103-108.	1.3	13
139	Reduced mitogenic stimulation of human lymphocytes by extremely low frequency electromagnetic fields. FEBS Letters, 1983, 162, 156-160.	1.3	103
140	Improved osteogenic differentiation by extremely low electromagnetic field exposure: possible application for bone engineering. Histochemistry and Cell Biology, 0, , .	0.8	1